---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-300211"
form_type: "8-K"
ticker: "VOR"
cik: "0001817229"
company_name: "Vor Biopharma Inc."
filed_at: "2022-12-07T23:59:59+00:00"
generated_at: "2026-06-21T08:15:36.923688+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vor Biopharma prices $115.8M combined stock offering and private placement at $4.30/share

## Summary
- 15.3M shares sold in underwritten offering for gross $65.8M; 11.6M shares in private placement to RA Capital for $50M.
- Net proceeds from underwritten offering estimated at $61.4M after discounts and expenses; private placement net not disclosed.
- Proceeds to fund clinical pipeline development and working capital; closings expected December 9, 2022.
- Private placement shares are unregistered; company must file resale registration by Jan 8, 2023 or issue warrants by Dec 31, 2022.
- Underwriters: Evercore, Stifel, Oppenheimer; RA Capital is company's largest stockholder.

## SEC filing metadata
- accession: 0001193125-22-300211
- form_type: 8-K
- ticker: VOR
- cik: 0001817229
- company_name: Vor Biopharma Inc.
- filed_at: 2022-12-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817229/000119312522300211/0001193125-22-300211-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817229/000119312522300211/d411199d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-300211
- JSON: https://secwatch.observer/filing/0001193125-22-300211.json
- Plain text: https://secwatch.observer/filing/0001193125-22-300211.txt

## Key facts
- Material Agreements
  Vor Biopharma Inc. entered into Securities Purchase Agreement with RA Capital Healthcare Fund, L.P. valued at approximately $50.0 million (effective 2022-12-07).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: RA Capital Healthcare Fund, L.P.
  - Value: approximately $50.0 million
  - Effective: 2022-12-07
  source text: On December 7, 2022, the Company entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with RA Capital Healthcare Fund, L.P. (“ RA Capital ”). Pursuant to the Securities Purchase Agreement, RA Capital agreed to purchase, and the Company agreed to issue to RA Capital 11,627,907 shares of Common Stock at a price of $4.30 per share (the “ Private Placement ”). The total purchase price shall be equal to approximately $50.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817229/000119312522300211/0001193125-22-300211-index.htm
- Material Agreements
  Vor Biopharma Inc. entered into Underwriting Agreement with Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated valued at approximately $61.4 million (effective 2022-12-07).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated
  - Value: approximately $61.4 million
  - Effective: 2022-12-07
  source text: On December 7, 2022, Vor Biopharma Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated, as representatives of the several underwriters listed on Schedule I thereto (collectively, the “ Underwriters ”), relating to an offering (the “ Offering ”) of 15,302,267 shares (the “ Shares ”) of the Company’s common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817229/000119312522300211/0001193125-22-300211-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.